Neuropace Inc (NPCE)

$16.75 +0.62 (3.84%)
Market Cap 537.26M
Revenue (ttm) 79.91M
Net Income (ttm) -27.14M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -33.96%
Debt to Equity Ratio 3.17
Volume 263,500
Avg Vol 275,110
Day's Range N/A - N/A
Shares Out 33.31M
Stochastic %K 60%
Beta 1.85
Analysts Strong Sell
Price Target $19.25

Company Profile

NeuroPace, Inc. operates as a medical device company in the United States. The company develops RNS system, a brain-responsive neuromodulation system that delivers personalized, real-time treatment at the seizure source for treating drug-resistant focal epilepsy. Its RNS System includes RNS neurostimulator, cortical strip and depth leads, and Patient Remote Monitor, as well as other implantable and non-implantable accessories. In addition, the company provides physician tablet and patient data m...

Industry: Medical Devices
Sector: Healthcare
Phone: 650 237 2700
Fax: 650 237 2701
Address:
455 North Bernardo Avenue, Mountain View, United States
JohnTrack
JohnTrack Jan. 13 at 4:51 PM
$NPCE little patience, still watching...
0 · Reply
JohnTrack
JohnTrack Jan. 13 at 12:45 PM
$NPCE headline ping live!!! https://www.rapidticker.com/news/npce-neuropace-reports-preliminary-unaudited-results-3b915a
0 · Reply
Grubnednarb
Grubnednarb Jan. 8 at 3:47 AM
$NPCE
0 · Reply
Scoops1212
Scoops1212 Jan. 7 at 6:05 PM
$NPCE This is about as frustrating of a stock that you can own. I’ve crunched all the numbers and this should be at 40+ right now there is something holding this price down, and it’s not visible in the numbers. Check their quarterly, and some big investors holding their position. When will this launch, as it’s long overdue?
0 · Reply
JohnTrack
JohnTrack Dec. 31 at 10:44 PM
$NPCE keeping tabs on sentiment!
0 · Reply
JohnTrack
JohnTrack Dec. 31 at 8:27 PM
$NPCE to Present at the 44th Annual J.P. Morgan Healthcare Conference https://www.rapidticker.com/news/npce-neuropace-to-present-at-the-30d93c
0 · Reply
OfficialStocktwitsUser
OfficialStocktwitsUser Dec. 29 at 11:20 AM
$NPCE RSI: 44.41, MACD: 0.5827 Vol: 0.38, MA20: 16.25, MA50: 13.84 🔴 SELL - Downtrend 👉 https://quantumstockalerts.com Disclaimer: I am not a financial advisor. This post reflects personal analysis and opinions only. Please do your own research before investing or trading.
0 · Reply
erevnon
erevnon Dec. 16 at 3:31 PM
UBS maintains NeuroPace $NPCE at Buy and raises the price target from $18 to https://marketsblock.com/stock-upgrades-and-downgrades/
0 · Reply
JarvisFlow
JarvisFlow Dec. 16 at 2:27 PM
UBS has adjusted their stance on NeuroPace ( $NPCE ), setting the rating to Buy with a target price of 18 → 22.
0 · Reply
JarvisFlow
JarvisFlow Dec. 10 at 4:00 PM
JP Morgan has updated their rating for NeuroPace ( $NPCE ) to Overweight with a price target of 20.
0 · Reply
Latest News on NPCE
NeuroPace, Inc. (NPCE) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript

Jan 14, 2026, 7:46 PM EST - 3 hours ago

NeuroPace, Inc. (NPCE) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript

NeuroPace Reports Preliminary Unaudited Results for the Fourth Quarter and Fiscal Year 2025 and Initial 2026 Outlook

Jan 13, 2026, 7:30 AM EST - 1 day ago

NeuroPace Reports Preliminary Unaudited Results for the Fourth Quarter and Fiscal Year 2025 and Initial 2026 Outlook

NeuroPace to Present at the 44th Annual J.P. Morgan Healthcare Conference

Dec 31, 2025, 9:00 AM EST - 14 days ago

NeuroPace to Present at the 44th Annual J.P. Morgan Healthcare Conference

NeuroPace Files PMA Supplement to FDA Seeking Expanded RNS® System Indication for Idiopathic Generalized Epilepsy

Dec 17, 2025, 8:00 AM EST - 4 weeks ago

NeuroPace Files PMA Supplement to FDA Seeking Expanded RNS® System Indication for Idiopathic Generalized Epilepsy

NeuroPace Announces Positive 18-Month NAUTILUS Trial Results in Idiopathic Generalized Epilepsy

Dec 8, 2025, 8:00 AM EST - 5 weeks ago

NeuroPace Announces Positive 18-Month NAUTILUS Trial Results in Idiopathic Generalized Epilepsy

NeuroPace to Highlight Life-Changing Outcomes and AI-Powered Confident Care at the 2025 American Epilepsy Society (AES) Annual Meeting

Dec 2, 2025, 8:01 AM EST - 6 weeks ago

NeuroPace to Highlight Life-Changing Outcomes and AI-Powered Confident Care at the 2025 American Epilepsy Society (AES) Annual Meeting

NeuroPace Announces Favorable Medicare Reimbursement Increases for RNS System Physician and Hospital Outpatient Services

Nov 24, 2025, 8:00 AM EST - 7 weeks ago

NeuroPace Announces Favorable Medicare Reimbursement Increases for RNS System Physician and Hospital Outpatient Services

NeuroPace, Inc. (NPCE) Q3 2025 Earnings Call Transcript

Nov 4, 2025, 11:06 PM EST - 2 months ago

NeuroPace, Inc. (NPCE) Q3 2025 Earnings Call Transcript

NeuroPace Reports Third Quarter 2025 Financial Results and Increases 2025 Revenue Guidance

Nov 4, 2025, 4:05 PM EST - 2 months ago

NeuroPace Reports Third Quarter 2025 Financial Results and Increases 2025 Revenue Guidance

NeuroPace to Report Third Quarter 2025 Financial Results on November 4, 2025

Oct 22, 2025, 8:00 AM EDT - 3 months ago

NeuroPace to Report Third Quarter 2025 Financial Results on November 4, 2025

NeuroPace to Participate in Upcoming Healthcare Conferences

Aug 28, 2025, 8:00 AM EDT - 4 months ago

NeuroPace to Participate in Upcoming Healthcare Conferences

NeuroPace, Inc. (NPCE) Q2 2025 Earnings Call Transcript

Aug 12, 2025, 9:50 PM EDT - 5 months ago

NeuroPace, Inc. (NPCE) Q2 2025 Earnings Call Transcript

NeuroPace Reports Second Quarter 2025 Financial Results and Increases 2025 Revenue Guidance

Aug 12, 2025, 4:05 PM EDT - 5 months ago

NeuroPace Reports Second Quarter 2025 Financial Results and Increases 2025 Revenue Guidance

NeuroPace Commends CMS for Maintaining FY25 Reimbursement Structure for Epilepsy with Neurostimulator Cases

Aug 1, 2025, 7:30 AM EDT - 5 months ago

NeuroPace Commends CMS for Maintaining FY25 Reimbursement Structure for Epilepsy with Neurostimulator Cases

NeuroPace Announces Strategic CFO Transition

Jun 24, 2025, 4:05 PM EDT - 7 months ago

NeuroPace Announces Strategic CFO Transition

NPCE Investors Have Opportunity to Join NeuroPace, Inc. Fraud Investigation with the Schall Law Firm

Jun 24, 2025, 3:42 AM EDT - 7 months ago

NPCE Investors Have Opportunity to Join NeuroPace, Inc. Fraud Investigation with the Schall Law Firm

Bronstein, Gewirtz & Grossman, LLC Is Investigating NeuroPace, Inc. (NPCE) And Encourages Shareholders to Connect

Jun 13, 2025, 10:00 AM EDT - 7 months ago

Bronstein, Gewirtz & Grossman, LLC Is Investigating NeuroPace, Inc. (NPCE) And Encourages Shareholders to Connect

Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against NeuroPace, Inc. (NPCE) And Encourages Shareholders to Reach Out

Jun 12, 2025, 10:00 AM EDT - 7 months ago

Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against NeuroPace, Inc. (NPCE) And Encourages Shareholders to Reach Out

Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against NeuroPace, Inc. (NPCE) and Encourages Shareholders to Learn More About the Investigation

Jun 11, 2025, 10:00 AM EDT - 7 months ago

Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against NeuroPace, Inc. (NPCE) and Encourages Shareholders to Learn More About the Investigation

NeuroPace, Inc. (NPCE) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Contact the Firm to Learn More About the Investigation

Jun 10, 2025, 10:00 AM EDT - 7 months ago

NeuroPace, Inc. (NPCE) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Contact the Firm to Learn More About the Investigation

NeuroPace, Inc. (NPCE) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Shareholders to Contact the Firm to Learn More About the Investigation

Jun 9, 2025, 10:00 AM EDT - 7 months ago

NeuroPace, Inc. (NPCE) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Shareholders to Contact the Firm to Learn More About the Investigation

Bronstein, Gewirtz & Grossman, LLC Is Investigating NeuroPace, Inc. (NPCE) And Encourages Investors to Connect

Jun 8, 2025, 10:00 AM EDT - 7 months ago

Bronstein, Gewirtz & Grossman, LLC Is Investigating NeuroPace, Inc. (NPCE) And Encourages Investors to Connect

Bronstein, Gewirtz & Grossman, LLC Encourages NeuroPace, Inc. (NPCE) Stockholders to Inquire about Securities Investigation

Jun 6, 2025, 10:00 AM EDT - 7 months ago

Bronstein, Gewirtz & Grossman, LLC Encourages NeuroPace, Inc. (NPCE) Stockholders to Inquire about Securities Investigation

Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against NeuroPace, Inc. (NPCE) and Encourages Investors to Learn More About the Investigation

Jun 5, 2025, 10:00 AM EDT - 7 months ago

Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against NeuroPace, Inc. (NPCE) and Encourages Investors to Learn More About the Investigation

NeuroPace Secures Up to $75 Million in Debt Financing

Jun 4, 2025, 4:09 PM EDT - 8 months ago

NeuroPace Secures Up to $75 Million in Debt Financing

Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against NeuroPace, Inc. (NPCE) And Encourages Stockholders to Reach Out

Jun 3, 2025, 10:00 AM EDT - 8 months ago

Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against NeuroPace, Inc. (NPCE) And Encourages Stockholders to Reach Out

Bronstein, Gewirtz & Grossman, LLC Is Investigating NeuroPace, Inc. (NPCE) And Encourages Stockholders to Connect

Jun 2, 2025, 10:00 AM EDT - 8 months ago

Bronstein, Gewirtz & Grossman, LLC Is Investigating NeuroPace, Inc. (NPCE) And Encourages Stockholders to Connect

NeuroPace, Inc. (NPCE) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Stockholders to Contact the Firm to Learn More About the Investigation

Jun 1, 2025, 10:00 AM EDT - 8 months ago

NeuroPace, Inc. (NPCE) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Stockholders to Contact the Firm to Learn More About the Investigation

Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against NeuroPace, Inc. (NPCE) and Encourages Stockholders to Learn More About the Investigation

May 30, 2025, 10:00 AM EDT - 8 months ago

Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against NeuroPace, Inc. (NPCE) and Encourages Stockholders to Learn More About the Investigation

Bronstein, Gewirtz & Grossman, LLC Encourages NeuroPace, Inc. (NPCE) Investors to Inquire about Securities Investigation

May 29, 2025, 12:45 PM EDT - 8 months ago

Bronstein, Gewirtz & Grossman, LLC Encourages NeuroPace, Inc. (NPCE) Investors to Inquire about Securities Investigation

Why Is NeuroPace Stock Falling After Epilepsy Treatment Study Data?

May 27, 2025, 12:48 PM EDT - 8 months ago

Why Is NeuroPace Stock Falling After Epilepsy Treatment Study Data?

NeuroPace Announces Preliminary Results from One-Year Data in NAUTILUS Study

May 27, 2025, 8:00 AM EDT - 8 months ago

NeuroPace Announces Preliminary Results from One-Year Data in NAUTILUS Study

NeuroPace, Inc. (NPCE) Q1 2025 Earnings Call Transcript

May 13, 2025, 10:33 PM EDT - 8 months ago

NeuroPace, Inc. (NPCE) Q1 2025 Earnings Call Transcript

NeuroPace Reports First Quarter 2025 Financial Results

May 13, 2025, 4:05 PM EDT - 8 months ago

NeuroPace Reports First Quarter 2025 Financial Results

NeuroPace Provides Update on Tariff Status

Apr 14, 2025, 4:05 PM EDT - 9 months ago

NeuroPace Provides Update on Tariff Status

NeuroPace Announces Data From a Long-Term Post-Approval Study of the RNS System in Focal Epilepsy at the 2025 AAN Annual Meeting

Apr 8, 2025, 8:00 AM EDT - 10 months ago

NeuroPace Announces Data From a Long-Term Post-Approval Study of the RNS System in Focal Epilepsy at the 2025 AAN Annual Meeting

NeuroPace Announces Upcoming Oral Presentation of Data from the Long-Term Post-Approval Study of the RNS System at the 2025 AAN Annual Meeting

Apr 3, 2025, 8:00 AM EDT - 10 months ago

NeuroPace Announces Upcoming Oral Presentation of Data from the Long-Term Post-Approval Study of the RNS System at the 2025 AAN Annual Meeting

NeuroPace Announces Refocusing of Product Portfolio

Apr 2, 2025, 4:05 PM EDT - 10 months ago

NeuroPace Announces Refocusing of Product Portfolio

JohnTrack
JohnTrack Jan. 13 at 4:51 PM
$NPCE little patience, still watching...
0 · Reply
JohnTrack
JohnTrack Jan. 13 at 12:45 PM
$NPCE headline ping live!!! https://www.rapidticker.com/news/npce-neuropace-reports-preliminary-unaudited-results-3b915a
0 · Reply
Grubnednarb
Grubnednarb Jan. 8 at 3:47 AM
$NPCE
0 · Reply
Scoops1212
Scoops1212 Jan. 7 at 6:05 PM
$NPCE This is about as frustrating of a stock that you can own. I’ve crunched all the numbers and this should be at 40+ right now there is something holding this price down, and it’s not visible in the numbers. Check their quarterly, and some big investors holding their position. When will this launch, as it’s long overdue?
0 · Reply
JohnTrack
JohnTrack Dec. 31 at 10:44 PM
$NPCE keeping tabs on sentiment!
0 · Reply
JohnTrack
JohnTrack Dec. 31 at 8:27 PM
$NPCE to Present at the 44th Annual J.P. Morgan Healthcare Conference https://www.rapidticker.com/news/npce-neuropace-to-present-at-the-30d93c
0 · Reply
OfficialStocktwitsUser
OfficialStocktwitsUser Dec. 29 at 11:20 AM
$NPCE RSI: 44.41, MACD: 0.5827 Vol: 0.38, MA20: 16.25, MA50: 13.84 🔴 SELL - Downtrend 👉 https://quantumstockalerts.com Disclaimer: I am not a financial advisor. This post reflects personal analysis and opinions only. Please do your own research before investing or trading.
0 · Reply
erevnon
erevnon Dec. 16 at 3:31 PM
UBS maintains NeuroPace $NPCE at Buy and raises the price target from $18 to https://marketsblock.com/stock-upgrades-and-downgrades/
0 · Reply
JarvisFlow
JarvisFlow Dec. 16 at 2:27 PM
UBS has adjusted their stance on NeuroPace ( $NPCE ), setting the rating to Buy with a target price of 18 → 22.
0 · Reply
JarvisFlow
JarvisFlow Dec. 10 at 4:00 PM
JP Morgan has updated their rating for NeuroPace ( $NPCE ) to Overweight with a price target of 20.
0 · Reply
SuperGreenToday
SuperGreenToday Dec. 9 at 9:37 PM
$NPCE Share Price: $16.26 Contract Selected: May 15, 2026 $17.5 Calls Buy Zone: $0.73 – $0.90 Target Zone: $1.36 – $1.66 Potential Upside: 76% ROI Time to Expiration: 156 Days | Updates via https://fxcapta.com/stockinfo/
0 · Reply
stockwitsuser2449
stockwitsuser2449 Dec. 1 at 12:35 PM
$NPCE
0 · Reply
stockwitsuser2449
stockwitsuser2449 Nov. 20 at 7:07 PM
$NPCE large drop here
1 · Reply
HypnoTrader
HypnoTrader Nov. 19 at 6:48 PM
$NPCE no way to confirm anything an anonymous account is telling you, but the chart seems to agree....
1 · Reply
HypnoTrader
HypnoTrader Nov. 19 at 6:46 PM
$NPCE
0 · Reply
johnemac
johnemac Nov. 19 at 6:45 PM
$NPCE In a sample size of one my son continues to be seizure-free since February and his RNS (NPCE's main product) surgery. In addition he is able now to wean back his meds considerably. Thank you Neuropace.
0 · Reply
Scoops1212
Scoops1212 Nov. 19 at 3:01 PM
$NPCE If you believe in the treatment, this is the time to go big. The numbers show this should be at $40, and is at $13. I’m not a pumper, and know how to crunch these numbers. This should be at $40 right now!
0 · Reply
BEATOFtheMARKET
BEATOFtheMARKET Nov. 17 at 10:54 AM
$NOG $NPCE $NRDS $NRT $NTCT
0 · Reply
stockwitsuser2449
stockwitsuser2449 Nov. 15 at 6:01 PM
$NPCE 15 strike put options working out so far
0 · Reply
Scoops1212
Scoops1212 Nov. 12 at 2:05 PM
$NPCE The big question is what does this company have to do financially, to beat their opening price over 4 years ago? They’ve had strong quarterly’s all but once, and they had never reached $20. What da?!
0 · Reply
Joby099
Joby099 Nov. 7 at 2:03 PM
$PLRZ $RIGL $NPCE $LITE
0 · Reply
stockwitsuser2449
stockwitsuser2449 Nov. 7 at 12:29 PM
$QURE $BIOA $DYN and $NPCE now. glta
0 · Reply